Are trajectories of depressive symptoms during the first half of drug-sensitive pulmonary tuberculosis treatment associated with loss to follow-up? A secondary analysis of longitudinal data

Ruiz-Grosso P.; Loret De Mola C.; Otero L.; Ugarte-Gil C. · BMJ Open (2023) · DOI: 10.1136/bmjopen-2022-068235

Resumen

Objective The objective of this study was to identify trajectories of depressive symptoms (DSs) during the first half of drug-sensitive pulmonary tuberculosis (PTB) treatment and examine their association with loss to follow-up (LTFU) in the second half. Design This study involved a secondary analysis of longitudinal data to identify potential trajectories of DS and their relationship with LTFU. Setting The study was conducted in first and second-level health centres located in San Juan de Lurigancho, Lima, Peru. Participants Anonymised data from 265 individuals, including monthly measures of DSs from diagnosis to the completion of treatment, initiation of treatment for multidrug resistant TB, LTFU or death, were collected. Results Three trajectories were identified: 'declining', 'growth' and 'high'. These trajectories were observed in 182 (68.7%), 53 (20%) and 30 (11.3%) of the 265 individuals, respectively, during the first half of PTB treatment. Compared with those with a 'declining' trajectory, individuals with a 'growth' trajectory had a higher likelihood of experiencing LTFU during the second half of PTB treatment, after controlling for sociodemographic factors and at least weekly alcohol use (OR 3.9; 95% CI 1.09 to 13.97, p=0.036). Conclusions The findings suggest that a trajectory of increasing DSs during the first half of PTB treatment is associated with a higher risk of LTFU during the second half. © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Instituciones: Universidad Peruana Cayetano Heredia